regulation3 hours ago
Treasury poised to tighten scrutiny on Chinese biotech acquisitions
The U.S. Treasury Department is expected to implement stricter rules governing Chinese biotechnology transactions, signaling a shift toward more rigorous oversight of cross-border pharmaceutical deals. This development follows months of industry efforts to avoid harsh regulatory treatment and comes amid heightened geopolitical tensions. While previous drafts suggested a distinction between standard licensing and sensitive technologies, the new framework is anticipated to impose tighter constraints on acquisitions and partnerships involving Chinese firms.